Inclusion Criteria:

- Patients who are confirmed to have 1-5 metastatic brain tumor by the latest
contrast-enhanced cerebral CT or contrast-enhanced cerebral MRI, and the lesion(s)
have not been treated by surgery or by stereotactic radiosurgery.

Exclusion Criteria:

- Patients who are scheduled to receive another contrast medium for MRI (except for
oral agents) or iodine contrast medium (except for oral agents), or to undergo
surgical procedures during the period from the day before administration of Magnevist
(SH L 451A) to examination of safety on the following day.

- Patients who underwent or are scheduled to undergo radiotherapy during the period
from 14 days before administration of Magnevist (SH L 451A) to examination of safety
on the following day.

- Patients who were treated or are scheduled to be treated with anti-cancer agents
(except for treatment only by the oral agents of the fixed dose continuously from 28
days or more before administration of Magnevist (SH L 451A)) during the period from
28 days before administration of Magnevist (SH L 451A) to examination of safety on
the following day.